Study of Carbetocin in PWS

Study Purpose

Carbetocin (LV-101) is an investigational drug that was created to have effects in the body like oxytocin.  Carbetocin is not approved in the United States, but is approved in some other countries for treatment of women with excessive bleeding after giving birth via caesarean section.

Results from a Phase 2 study evaluating Carbetocin for PWS have been published and results were favorable.  Further development, including the Phase 3 study, will be pursued by Levo Therapeutics.  The Phase 3 study is expected to enroll individuals with PWS, age 7-18 years old, who will receive carbetocin or placebo by intranasal spray. Effects on hyperphagia (excessive appetite), will be measured.  An 'open label' period, where all participants can receive carbetocin for at least a year, is planned.  Plans for the Phase 3 study are subject to change.

Recruitment Criteria

Study Type: protocol not yet available
Eligible Ages: 7-18 years (estimated)
Other Criteria:

Trial Details

Trial Id
Phase: 3
Duration:  protocol not yet available
 not yet recruiting
Lead Sponsor: Levo
Countries: United States
Additional Details: 

Eligibility Criteria

not yet available

This Study is enrolling at the following sites:

not yet available

Tools for PWS Awareness

Volunteer Your Time

No matter how big or how small, every effort helps us!